Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

ROCHE HOLDING LTD. (ROG)
Mes dernières consult.
Most popular
Report
Delayed Quote. Delayed  - 01/19 05:31:21 pm
234.5 CHF   +0.56%
09:39a ROCHE : College basketball
01/15 BIOGEN : Roche's Ocrevus receives EU approval for MS
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
01/15/2018 01/16/2018 01/17/2018 01/18/2018 01/19/2018 Date
244.4(c) 236(c) 233.35(c) 233.2(c) 234.5(c) Last
1 870 299 4 612 399 3 320 698 2 762 510 2 809 217 Volume
-0.57% -3.44% -1.12% -0.06% +0.56% Change
More quotes
Financials ( CHF)
Sales 2017 53 460 M
EBIT 2017 18 172 M
Net income 2017 11 159 M
Debt 2017 9 887 M
Yield 2017 3,66%
Sales 2018 55 567 M
EBIT 2018 19 121 M
Net income 2018 12 352 M
Debt 2018 5 860 M
Yield 2018 3,84%
P/E ratio 2017 17,50
P/E ratio 2018 16,04
EV / Sales2017 3,99x
EV / Sales2018 3,77x
Capitalization 204 B
More Financials
Company
Roche Holding AG operates as a research healthcare company.It operates through the following segments: Diagnostics and Pharmaceuticals.The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience.The... 
Sector
Pharmaceuticals
Calendar
02/01 | 07:00amEarnings Release
More about the company
Surperformance© ratings of Roche Holding Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING LTD.
09:39a ROCHE : College basketball
01/20 EXTENSION OF THE EXTRACURRICULAR ACT : flexible floor, following unsuccessful co..
01/19 SYNDAX PHARMACEUTICALS : Announces Clinical Collaboration to Evaluate Entinostat..
01/19 FOUNDATION MEDICINE : Reports Preliminary 2017 Results
01/18 ROCHE : Miscellaneous structures
01/17 ROCHE : Niger gov's wife express dismay over poor cancer care
01/17 MERCK AND : Keytruda aces another lung cancer study
01/17 MERCK AND : Mercks Keytruda combo wows again, acing PhIII overall survival goal ..
01/17 Pfizer Joins Foundation Medicine to Develop Cancer CDx
01/17 Pfizer puts Foundation Medicine at the center of its cancer companion diagnos..
More news
Sector news : Pharmaceuticals - NEC
01/19 CANADIAN CANNABIS FIRM AURORA IN TAL : sources
01/19 En route to Davos, Macron makes Versailles the place to be
01/19 SHIRE PLC SHIRE PLC : Directorate Change
01/19 At AstraZeneca, fewer drug projects bring big productivity jump
01/18 European shares edge higher as cyclicals back in favour
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on ROCHE HOLDING LTD. 
ROCHE HOLDING LTD. - 2016
An opportunity over the medium term?
BUY
ROCHE HOLDING LTD. - 2016
A medium term support level to take advantage of
BUY
More Strategies
Latest Tweets
01/20Writing about Leslie Buckley; Sean Dunne and the 'vendetta'; an interesting V..
7
01/20A device developed by Roche Diagostics will help medical professionals determ..
10
01/19WBZ’s Dan Roche Named Mass. Sportscaster Of The Year
82
01/19Roche's Tecentriq OK'd in Japan for lung cancer  
01/19Mags Roche's Warm Duck Salad -  
More tweets
Qtime:242
News from SeekingAlpha
01/20 YOUR DAILY PHARMA SCOOP : Ablynx Takeover Battle, Acorda Takeover Speculation, O..
01/19 Key events next week - healthcare
01/19 Roche's Tecentriq OK'd in Japan for lung cancer
01/18 EC OKs Amgen's Avastin biosimilar
01/18 Big Biopharma in the red in early trade
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 273  CHF
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-5.40%211 135
JOHNSON & JOHNSON5.20%395 886
NOVARTIS0.61%227 592
PFIZER2.65%220 189
MERCK AND COMPANY10.24%167 132
AMGEN8.11%137 400